APM
TRML

Avidity Partners Management’s Tourmaline Bio TRML Stock Holding History

Avidity Partners Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-45,504
Closed -$6.96M – 111
2021
Q4 		$6.96M Buy
45,504
+4
+0% +$592 0.15% 69
2021
Q3 		$6.17M Buy
45,500
+1,864
+4% +$255K 0.14% 79
2021
Q2 		$6.41M Buy
+43,636
New +$6.68M 0.17% 86

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Avidity Partners Management's TRML Position: Q1 2022 in Review

Avidity Partners Management sold out of Tourmaline Bio (TRML) in Q1 2022, closing a stake of 45,504 shares — an estimated $6.96M sold.

Avidity Partners Management first reported a position in TRML in Q2 2021 and held it in 3 quarters. The position peaked at $6.96M in Q4 2021. 51 funds tracked by Wall St. Rank hold TRML as of Q1 2022.

  • Avidity Partners Management reported no remaining Tourmaline Bio position as of Q1 2022 after selling out during the quarter.
  • Avidity Partners Management sold 45,504 Tourmaline Bio shares in Q1 2022, an estimated $6.96M.
  • Avidity Partners Management first reported a position in Tourmaline Bio in Q2 2021 and held it in 3 quarters.
  • Avidity Partners Management's Tourmaline Bio position peaked at $6.96M in Q4 2021.
  • 51 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2022.

Based on Avidity Partners Management's 13F filing for Q1 2022, filed 16 May 2022.